Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials
This systematic review and meta-analysis compared the effectiveness of levonorgestrel-releasing intrauterine systems with oral progestins for treating non-atypical endometrial hyperplasia in randomized trials.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (43)
- Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. via openalex
- Endometrial hyperplasia treated by progestins. via openalex
- Levonorgestrel-Releasing Intrauterine Device Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia via openalex
- Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia. via openalex
- LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial via openalex
- Pharmacological profile of progestins via openalex
- TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD via openalex
- W1975611813 via openalex
- W1989426617 via openalex
- W2000516822 via openalex
- W2015334359 via openalex
- W2020609819 via openalex
- W2022945903 via openalex
- W2022987638 via openalex
- W2024827041 via openalex
- W2025504334 via openalex
- W2035680556 via openalex
- W2037004008 via openalex
- W2039249853 via openalex
- W2044060855 via openalex
- W2046383890 via openalex
- W2059180789 via openalex
- W2059313060 via openalex
- W2068050858 via openalex
- W2086934638 via openalex
- W2089514603 via openalex
- W2097113048 via openalex
- W2101959253 via openalex
- W2156098321 via openalex
- W2170038564 via openalex
- W2520626403 via openalex
- W2935754454 via openalex
- W2991792334 via openalex
- W6640427068 via openalex
- W6678166589 via openalex
- W140268124 via openalex
- W6696461104 via openalex
- W1520732112 via openalex
- W1598602811 via openalex
- W1924743946 via openalex
- W1966716045 via openalex
- W1966885175 via openalex
- W1974764886 via openalex
Cited by (12)
- Особенности клинического течения гиперпластических процессов эндометрия в разных возрастных группах 2025
- The efficacy of levonorgestrel intrauterine device, medroxyprogesterone acetate, and norethisterone acetate in the treatment of endometrial hyperplasia without atypia 2024
- Proliferative Endometrium in Menopause 2023
- Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis 2023
- Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia 2022
- Prise en charge des ménorragies : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) 2022
- Beyond Birth Control: Noncontraceptive Benefits of Hormonal Methods and Their Key Role in the General Medical Care of Women 2020
- Comparison between Different Diagnostic Strategies in Low-Risk Reproductive Age and Pre-Menopausal Women Presenting Abnormal Uterine Bleeding 2020
- The effect of progesterone, progestins, and menopausal hormone therapy on the endometrium in peri- and postmenopause 2019
- Levonorgestrel-releasing intrauterine system for endometrial hyperplasia 2017
- Erratum: HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia 2016
- HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia 2016
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00